Src mediates acquired resistance to ALK inhibitor in ALK-rearranged non-small cell lung cancers

被引：0
|
作者：
Yoshida, Ryohei
Okumura, Shunsuke
Sasaki, Takaaki
Osaki, Yoshinobu
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2121
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Brigatinib, a new treatment option in ALK-rearranged advanced non-small cell lung carcinoma
    Leprieur, Etienne Giroux
    Wislez, Marie
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S173 - S176
  • [42] Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus
    Cappuzzo, Federico
    Moro-Sibilot, Denis
    Gautschi, Oliver
    Boleti, Ekaterini
    Felip, Enriqueta
    Groen, Harry J. M.
    Germonpre, Paul
    Meldgaard, Peter
    Arriola, Edurne
    Steele, Nicola
    Fox, Jesme
    Schnell, Patrick
    Engelsberg, Arne
    Wolf, Juergen
    LUNG CANCER, 2015, 87 (02) : 89 - 95
  • [43] Imaging Features and Metastatic Patterns of Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    Mendoza, Dexter P.
    Lin, Jessica J.
    Rooney, Marguerite M.
    Chen, Tianqi
    Sequist, Lecia V.
    Shaw, Alice T.
    Digumarthy, Subba R.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2020, 214 (04) : 766 - 774
  • [44] Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer
    Ando, Chihiro
    Ichihara, Eiki
    Nishi, Tatsuya
    Morita, Ayako
    Hara, Naofumi
    Takada, Kenji
    Nakasuka, Takamasa
    Watanabe, Hiromi
    Kano, Hirohisa
    Nishii, Kazuya
    Makimoto, Go
    Kondo, Takumi
    Ninomiya, Kiichiro
    Fujii, Masanori
    Kubo, Toshio
    Ohashi, Kadoaki
    Matsuoka, Ken-ichi
    Hotta, Katsuyuki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    CANCER SCIENCE, 2023, 114 (11) : 4343 - 4354
  • [45] Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions
    Laird Cameron
    Benjamin Solomon
    Drugs, 2015, 75 : 1059 - 1070
  • [46] ALK-rearranged non-small cell lung cancer is associated with a high rate of venous thromboembolism
    Zer, A.
    Hershko-Klement, A.
    Hwang, D.
    Korpanty, G.
    Leighl, N.
    Liu, G.
    Feld, R.
    Burkes, R.
    Tsao, M.
    Shepherd, F.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S134 - S134
  • [47] Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    McKeage, Kate
    DRUGS, 2015, 75 (01) : 75 - 82
  • [48] Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma
    Caumont, Charline
    Veillon, Remi
    Gros, Audrey
    Laharanne, Elodie
    Begueret, Hugues
    Merlio, Jean-Philippe
    LUNG CANCER, 2016, 92 : 15 - 18
  • [49] ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism
    Zer, Alona
    Moskovitz, Mor
    Hwang, David
    Hershko-Klement, Anat
    Fridel, Ludmila
    Korpanty, Grzegorz
    Dudnik, Elizabeth
    Peled, Nir
    Shochat, Tzippy
    Leighl, Natasha
    Liu, Geoffrey
    Feld, Ronald
    Burkes, Ronald
    Wollner, Mira
    Tsao, Ming
    Shepherd, Frances
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S326 - S327
  • [50] Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    Kate McKeage
    Drugs, 2015, 75 : 75 - 82
12345